Drug intelligence / Profile preview

YHR2402 + YHR2403

Development stage: Phase 1
Lead developer: Yuhan

Overview

YHR2402 + YHR2403 is a combination of two investigational drugs developed by Yuhan. This combination is currently being studied in healthy volunteers to evaluate pharmacokinetic interactions and safety when the two agents are co-administered compared to administration of YHR2402 alone. Both components are in early clinical development, and their specific mechanisms of action, molecular targets, modalities, and intended therapeutic indications have not been publicly disclosed as of June 2025. The available data comes from a Phase 1 open-label, randomized crossover study involving healthy subjects[1][2][5][6].

Beyond the preview

Go deeper on YHR2402 + YHR2403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHR2402 + YHR2403.